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Abstract
68Gallium prostate specific membrane antigen (PSMA) ligand positron emission tomography (PET) is an increasingly
used imaging modality in prostate cancer, especially in cases of tumor recurrence after curative intended therapy.
Owed to the novelty of the PSMA-targeting tracers, clinical evidence on the value of PSMA-PET is moderate but
rapidly increasing. State of the art imaging is pivotal for radiotherapy treatment planning as it may affect dose
prescription, target delineation and use of concomitant therapy.
This review summarizes the evidence on PSMA-PET imaging from a radiation oncologist’s point of view. Additionally
a short survey containing twelve examples of patients and 6 additional questions was performed in seven mayor
academic centers with experience in PSMA ligand imaging and the findings are reported here.
Keywords: PSMA-PET, Prostate-cancer, Salvage radiotherapy, Primary radiotherapy, Image guided treatment planning,
Review, Survey
Background
Positron emission tomography (PET) imaging with
68Gallium-labeled prostate specific membrane antigen
ligands (PSMA) for prostate cancer patients has entered
clinical practice for staging prior to radiotherapeutic
treatment, especially for high-risk tumors and patients
suffering biochemical recurrence after surgery. As PET
is usually performed in combination with computed
tomography (CT) for attenuation correction and ana-
tomical information, the term PSMA PET is subse-
quently used as an abbreviation for this combined
examination, unless otherwise stated. PSMA-PET has a
higher specificity and sensitivity for the detection of
tumor lesions compared to stand alone CT, magnetic
resonance imaging (MRI) and Choline-PET. It offers
promising opportunities for treatment individualization
[1, 2]. PSMA-PET (CT/MRI) was introduced in 2012
[3–5]. Its clinical use and the scientific interest in
PSMA-PET imaging increased almost exponentially as
suggested by a Pubmed search using the terms PSMA
PET (Fig. 1). Due to the relative novelty of this radio-
tracer there is a steadily increasing clinical evidence for
the implementation of PSMA PET for clinical decision
making and radiotherapeutic target volume delineation.
Despite sparse high-grade evidence, it was shown that
PSMA-PET imaging had influence on radiotherapy treat-
ment in more than 48% of high risk patients (treatment-
naïve and recurrent prostate cancer) [6]. In two recent
publications with 161 and 270 patients suffering biochem-
ical recurrence Calais and colleagues reported intended
treatment management changes in more than 50% of pa-
tients. In case of early biochemical recurrence (defined as
PSA < 1.0 ng/ml) there was still a major impact of further
treatment planning in 19% of patients [7, 8].
This review focuses on the use of PSMA-PET for
radiotherapy planning and treatment, based on the
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clinically most widely used 68Gallium-labeled PSMA
ligands. The probably most important issues regarding
PSMA-PET for radiation oncologist are: When to use
PSMA-PET imaging for treatment planning/ staging and
how to optimally adapt radiotherapy planning to PSMA-
PET findings. The limitations and caveats of 68Gallium-
PSMA ligand and methods to improve imaging quality
and detection rates by alternative acquisition protocols or
PSMA conjugates are only briefly mentioned as they were
already comprehensively discussed elsewhere [9–12].
PSMA-PET for primary staging and definitive radiotherapy
The role of PSMA-PET for primary staging of prostate
cancer is less well defined as the potential important role
for biochemical recurrence after treatment with curative
intent. In a prospective multicenter assessment on treat-
ment modification by PSMA-PET in 108 treatment-
naïve intermediate and high-risk patients, PSMA-PET
led to treatment modifications in 21% [13]. Surprisingly,
there was no statistical significant difference of treat-
ment alterations between intermediate and high-risk pa-
tients in this largest published prospective cohort of
primary staged patients. Dewes and colleagues reported
on 15 patients treated with definitive radiotherapy. The
radiotherapeutic concept was changed in 33% of patients
due to the PSMA-PET CT, mostly leading to additional
target volumes/ dose escalation due to detected pelvic
lymph node metastases [14].
In a meta-analysis on the role of PSMA-PET for primary
staging of prostate cancer, von Eyben and colleagues iden-
tified seven studies, mostly retrospective analyses of
consecutive patients. PSMA-expressing lesions were only
identified in 203 of 273 patients (74%): 60% had lesions
confined to the prostate, 4% pelvic lymph nodes and 10%
presented lesions in more than one site, i.e. treatment was
probably adapted in around 14% of patients [2]. This intri-
guingly low number of PSMA expression within the
primary tumor lesions requires a closer look at the men-
tioned publications. Some of the seven reviewed studies
apparently only received dissection of pelvic lymph nodes
with unknown treatment status of the primary tumor:
Budäus et al. focused on lymph node detection rates and
didn’t explicitly report on primary tumors, additionally
even patients with prostate specific antigen (PSA) values
as low as 1.4 ng/ml were included [15]. Similarly, the ana-
lyses of Herlemann et al. and van Leeuwen et al. were re-
stricted to lymph node detection [16, 17]. Fendler et al.
reported a detection rate of intraprostatic PMSA lesions
of 90% (19 of 21 patients) [18]. Maurer et al. reported a
positive detection rate within the prostate of 91.6% in an
analysis of 130 patients [19]. Rhee et al. reported lesion
based analyses only [20]. The probably most interesting
study from a radiation oncologists perspective from Zam-
boglou et al. reported PSMA-PET based delineation. In 22
of 23 patients a gross tumor volume could be generated
by the use of PSMA-PET: Only in one patient no target
volume could be delineated based on PSMA PET. This
means 95% of patients would have had potentially suspi-
cious PSMA uptake within the prostate [21].
In summary these data show that the detection rate of
intraprostatic PSMA-positive lesions should be up to
95% (when primary lesions are separately analyzed as
discussed above). Nevertheless, sensitivity for detection
of every intraprostatic cancer focus (i.e. pathological
confirmed tumor localization) remains relatively low
with a pooled sensitivity around 70% and a specificity
around 84% [2]. Rhee, Eiber, Zamboglou and colleagues
compared multiparametric MRI, PSMA-PET and detec-
tion of histologic lesions: PSMA-PET outweighed MRI,
but in a relevant number of cases MRI and PSMA-PET
delivered complementary information on localization of
lesions [20, 22, 23]. Since PSMA uptake correlated with
features of tumor aggressiveness like extracapsular infil-
tration or Gleason score, a miss of small or lower grade
intraprostatic lesions may be acceptable for radiotherapy
treatment planning [18], as PET volumes would cur-
rently only be used to deliver a boost dose within the
prostate. Poorly differentiated prostate cancer cells are
known to be more radioresistant than well differentiated
ones, hence higher Gleason scores were associated with
markers of radioresistance and increased rates of local
recurrences after primary radiotherapy in some but not
all studies [24–27]. Therefore, higher radiation doses
(e.g. by a PET based boost) are potentially only needed
for tumors showing aggressive features while the lower
(standard) dose to the surrounding prostate should be
sufficient to treat small or low grade lesions.
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Fig. 1 Number of results for the search term “psma pet” in
pubmed.gov with annual publication date restrictions starting from
January 2014 until July 2017 (x-axis) and logarithmic depiction of
cumulative publications (y-axis)
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The concept of biological guided dose escalation (i.e.
prescription of radiation dose according to voxelwise PET
tracer uptake) was first propagated more than 10 years
ago [28]. Most studies on PET guided dose-painting fo-
cused on 18F-fluorodesoxyglucose (FDG) or hypoxia PET
tracers. However, many concerns have been raised about
the utility of the latter one for dose-painting, as the lesion
to background ratio is usually low and stability of the
tracer distribution within the tumor doubtful. This may be
a reason why no practice changing studies on dose-
painting approaches have been published so far. PSMA li-
gands seem to be promising tracers for radiotherapeutic
dose-escalation as the correlation with histopathological
findings is relatively high [18, 23, 29]. Dose-escalation for
definitive treatment of prostate cancer has shown to pro-
vide relevant improvement of progression free survival, al-
beit at the cost of higher early and potentially more
pronounced late toxicities [30, 31]. In a study by Budäus
and colleagues intraprostatic foci were correctly predicted
by PSMA-PET imaging before radical prostatectomy in
93% of patients in an analysis of 30 patients [15]. Semi-
automatic PSMA contouring with an intraprostatic
threshold of 30% of the intraprostatic SUVmax, used for
gross tumor delineation, was proven to be technically feas-
ible and would be relatively easy reproducible e.g. within a
multi-center trial [32]. Additionally, the level of PSMA lig-
and uptake correlated with established risk factors like
Gleason or d’Amico risk groups [33] and histological stud-
ies proved that cellular PSMA expression and PET uptake
correlated with features of tumor aggressiveness [34].
Multi-parametric dose-painting for prostate cancer using
MRI and PET information is technically feasible; however,
MRI and PET often show a relatively large overlap.
Furthermore, it remains unknown if the additional in-
formation of MRI and PET imaging adds information for
treatment planning which would be clinically meaningful
[35, 36]. A planning study on PSMA-PET based dose-
escalation within sub-volumes of the prostate by Zamboglou
and colleagues showed a promising increase of tumor con-
trol probability, without negatively affecting normal tissue
complication probabilities in modeled patients [32].
Although PSMA-PET has higher detection rates of lymph
node metastases compared to conventional imaging or
Choline-PET, due to the inherent limitation of PET im-
aging, microscopic spread or affected small volume lymph
nodes are potentially missed by PET imaging. Pooled com-
parison with surgical specimens revealed a high specificity
of 97%, but a moderate sensitivity of around 61% [2]. How-
ever, sensitivity is improved compared to CT, MRI or
Choline-PET imaging [37–41]. One study reported a
median diameter of false-negative lymph nodes (i.e. PSMA-
PET negative but histopathological positive) of only 1.3 mm
[42]. However, a negative finding in PSMA-PET is not able
to rule out metastatic spread within tiny lymph nodes.
For the detection of distant (bone) metastases, PSMA-
PET has a higher detection rate than standard bone
scintigraphy regarding lesion number [43]. Additional
bone scans seem to be dispensable if a PSMA-PET was
performed [44].
PSMA-PET for PSA persistence or biochemical recurrence
after radical prostatectomy
Salvage radiotherapy for biochemical recurrent disease
should be performed as early as possible [45–47]. How-
ever, detection rates for PSMA-PET depend highly on
PSA levels. While salvage radiotherapy should optimally
be initiated with PSA levels < 0.5 ng/ml [47], the rate of
PSMA positive tumor manifestation is relatively low in
this PSA range. Afshar-Oromieh and collegues reported
on 1007 consecutive patients and found PSMA-positive
lesions in 48% for PSA values ≤0.5 ng/ml and 73% for
PSA values between 0.5 ng/ml and 1.0 ng/ml [48], simi-
larly Eiber and colleagues reported a positive detection
rate of 57.9% [49]. Rauscher and colleagues recently
published data of 272 patients with early biochemical re-
currence. PSMA positive lesions were evident in 55% of
patients with PSA values between 0.2 and 0.5 ng/ml and
74% of patients with PSA values between 0.5 and 1.0 ng/ml
[50]. Other studies with smaller sample sizes reported a
positive detection rate of 44% for PSA values < 1 ng/ml
and 48% for PSA values < 0.8 ng/ml [51, 52]. Therefore,
based on the largest series of patients from Afshar-
Oromieh and collegues, PSMA-PET should probably be
performed in case of PSA levels > 0.5 ng/ml due to the
relatively high detection rates of 70% or more. However, in
some cases PSMA-PET detects lesions even in patients
with very low PSA values: An analysis of 70 patients re-
ported relatively high detection rates of 58% even for PSA
values between 0.20–0.29 ng/ml [53]. A limitation of these
studies is that patients receiving salvage radiotherapy for
biochemical recurrence were not separately analyzed from
patients receiving salvage radiotherapy for postoperative
persisting PSA levels. Additionally, detailed information on
concomitant ADT use was often missing. In cases of very
high risk situations for regional or distant spread, e.g. R0
resection and persisting PSA values, PSMA-PET might be
performed even with PSA values < 0.5 ng/ml. This pre-
selection of patients with low risk for isolated local
recurrence may be useful since detection of small lesions
around the former prostate gland can be difficult due to
the high urinary bladder spillover [9]. This constraint can
only partially be resolved by images at later time points
(tracer dilution).
PSMA-PET leads to radiotherapy treatment modifica-
tion in up to 59% of cases presenting with biochemical
recurrence at the radiation oncology department, as re-
ported in a recent publication that included 100 patients
with a median PSA level of 1.0 ng/ml [54]. Similar rates
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of radiotherapy adaptation were found in other publica-
tions with smaller sample sizes [6, 41, 55]. Interestingly,
PSMA-positive lymph nodes would not be covered by
delineation of the pelvic lymphatic drainage according to
RTOG lymph node target volume recommendations in
up to 40% of cases [56, 57]. The ever increasing
experience with PSMA-PET imaging may on the long
run lead to alterations of the recommended pelvic target
volume delineation.
A current Australian study reported a cohort of 164 pa-
tients referred for salvage radiotherapy. PSA levels were
between 0.05 and 1 ng/ml and PSMA positive lesions were
detected in 61%. PSA response after salvage radiotherapy
in patients not receiving androgen deprivation therapy
was highest in case of missing evidence of PET lesions or
disease limited to the prostate fossa, with 86 and 83% re-
spectively. Nodal involvement reduced response rate to
62% (after nodal irradiation) and distant metastases fur-
ther reduced post-radiotherapeutic response to 30% [58].
However, this may only be true in case of relatively low
PSA values up to 1 ng/ml, as another publication that in-
cluded patients with higher PSA values reported a poten-
tial unfavourable PSA response after radiotherapy limited
to the prostatic region in case of negative PSMA findings
for these patients [59].
Table 1 summarizes the current literature on biochem-
ical response after PSMA guided radiotherapy. Although
low patient numbers and a short follow-up are common
limitations to all studies, some cautious conclusions may
already be drawn: For low PSA values, salvage radiother-
apy of the prostate fossa should not be omitted in case
of PSMA-negativity. The probability of lasting PSA re-
sponse after radiotherapy is probably highest for local
recurrence, intermediate for regional and distant lymph
node recurrences and lowest for bone metastases.
Nevertheless, some patients with distant metastases
seem to present an intermediate-term PSA response. At
the moment, it is not predictable which patients with
distant metastases benefit most likely from high-dose
PSMA based radiotherapy.
PSMA-PET for the treatment of (oligo-)metastatic prostate
cancer
The concept of oligometastases was introduced by
Hellman and Weichselbaum in 1995. They stated that
“as effective chemotherapy becomes more widely applic-
able, there should be another group of patients with oli-
gometastases. These are patients who had widespread
metastases that were mostly eradicated by systemic
agents, the chemotherapy having failed to destroy those
remaining because of the number of tumor cells, the
presence of drug-resistant cells, or the tumor foci being
located in some pharmacologically privileged site” [60].
Due to the high detection rate of prostate cancer man-
ifestations, PSMA-PET seems to be highly promising for
detection and treatment of oligometastatic disease. First
retrospective data on the treatment of oligometastases
was published by Habl et al.: They analyzed 15 patients
with a total of 20 bone metastases who underwent high-
dose stereotactic radiotherapy and reported a median
biochemical progression free survival of 6.9 months [61].
Several prospective studies on the role of radiotherapy
to oligometastatic lesions are currently recruiting [62].
PSMA based irradiation of gross PSMA-positive tumor
lesions may even have a potential to restore hormone-
response: PSMA expression is upregulated after andro-
gen deprivation therapy (ADT) and higher expressed in
biological more aggressive tumors [63]. Selective pres-
sure on tumor cells by ADT may lead to (oligo-) pro-
gressive high PSMA expressing disease [64]. A recent
publication reported one case of restored hormone-
response after radioligand therapy [65]. PSMA based
irradiation of bulky disease may be a promising
approach in oligo-recurrent/ progressive disease after
Table 1 First reports on biochemical response following PSMA based radiotherapy after prior radical treatment of the prostate
Referal for salvage/ non primary radiotherapy, PSA response
Author Number of
irradiated
patients
Treatment of Median PSA
value
ADT use before
radiotherapy
Follow up time
(months)
PSA response
during follow up
Re-Radiation ADT initiation
during follow up
Henkenberens [69] 23 N, Ma, 2.75 0% 12.4 52% 26% 22%
Zschaeck [59] 20 (11) T, N, Ma, Mb 0.95 45% (0%) 29.0 70% (73%) 15% (27%) 5% (9%)
Bluemel [70] 43 T, N, Ma, Mb 0.60 0% 8.1 83%a 0% n.a.
Emmett [58] 99 T, N, Ma, Mb 0.28 0% 10.5 72% n.a. n.a.
Habl [61] 15 Mb 1.99 20% 22.5 20% 7% n.a.
Henkenberens [71] 29 T, N, Ma, Mb 1.47 38% 8.3 96% 7% 0%
Guler [68] 23 N, Ma, Mb 1.10 100% (43%b) 7.0 83% 0% 9%
T = local recurrence, N = pelvic lymph nodes, Ma = extrapelvic lymph nodes, Mb = bony metastases. ADT androgen deprivation therapy
aFollow up only available for 21 patients: 20 presenting good response, however 3 patients with rising PSA values during salvage irradiation were included to the
non-responders (4/24 patients)
b43% of patients presented with hormone refractory situation after long-term ADT
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ADT. Pre-clinical studies and some clinical data re-
ported enhanced cellular PSMA expression after ADT
and a potential association of castration-resistant status
and increase of PSMA expression. Additionally, maximal
PSMA standardized uptake values (SUVmax) of hormone
refractory oligometastatic patients were higher than
these of castration sensitive patients [63, 66–68]. A re-
cent publication describing 23 patients treated for evi-
dence of oligometastatic prostate cancer on PSMA-PET
included 10 castration resistant patients with Median
PSA values of Median 5.5 ng/ml [68]. In this poor prog-
nosis group the authors reported a median progression
free survival of 7 months. However, it remains unclear
how progression was classified. A closer look at the pa-
tients revealed that 9 out of 10 patients had lower PSA
values during follow-up compared to the value before
radiotherapy. Five of them presented PSA decreases > 50%
at the last follow up visit. In this small group this rate was
quite favorable when compared to PSA decreases in only
8 out of 13 hormone-sensitive patients.
Current practice
We performed a short survey containing twelve short
example cases depicting typical clinical scenarios and 6
additional questions (opinion on the value of PSMA-
PET, effect of PSMA-PET on treatment) in seven mayor
university centers with experience in PSMA-PET im-
aging. Based on clinical parameters and findings of
PSMA-PET we asked for an institutional consensus to
suggest treatment recommendations but accepted alter-
native answers if no consensus was achievable. Twelve
questionnaires were included for evaluation. All partici-
pants were experienced radiation oncologists with a
median time of 10 years in practice and 3 years of ex-
perience with PSMA based radiotherapy. Since case re-
ports were relatively short many radiation oncologists
demanded additional MRI imaging or pathological
information. The detailed information on the patient
cases and the respective answers can be found in
Additional file 1. When asked for the influence of
PSMA-PET on radiotherapeutic management, it was
considered to alter treatment in 60% of cases (median).
In case of PSA persistence or recurrence without
evidence of PSMA-positive lesions, the large majority of
radiation oncologists would opt for salvage radiation
of the prostate fossa (100% in case of PSA recurrence
of 0.26 ng/ml and 92% in case of PSA persistence or PSA
recurrence with a PSA value of 2.9 ng/ml). Interestingly,
in the latter case 83% would recommend additional an-
drogen deprivation therapy, while only 18% would recom-
mend additional irradiation of the lymphatic drainage.
Remarkably, a very high unanimity existed in case of
PSMA evidence of positive pelvic nodes: 92–100% would
recommend radiation of prostate fossa, pelvic lymphatic
drainage and boost of PSMA positive lesions, with
additional androgen deprivation therapy being recom-
mended by most centers irrespective of surgical resec-
tion status. In case of two para-aortic lymph node
metastases in a R1 resected patient with a Gleason score
of 7 an pN+, PSA persistence and a PSA value before
radiotherapy of 1.6 ng/ml, most radiation oncologists
would recommend ADT (92%) with one limiting the
treatment to ADT only. The majority would additional
irradiate pelvic lymphatic drainage (75%) and para-aortic
nodes (83%), while only 58% would recommend to
additionally irradiate the prostate fossa. Only 18% would
(alternatively) offer stereotactic ablative radiotherapy of
the two lymph nodes. In case of the same para-aortic
findings, but in a heavily pre-treated patient (surgery,
radiotherapy to the fossa, ADT and hormone-refractory
situation with PSA of 0.72 ng/ml) most radiation on-
cologist would opt for intensification of systemic
treatment (18% would only recommend this treatment
without any radiotherapy), but still 83% would irradiate
PSMA-PET findings either as a boost to para-aortal
nodes (67%) or by stereotactic radiotherapy (18%). If the
same patient would present without para-aortal but with
three lymph nodes restricted to the pelvis 92% would
recommend irradiation of pelvic lymphatic drainage with
a boost to PSMA positive lesions and 75% (additional)
systemic treatment intensification.
In case of a patient with Gleason score of 8 and R0
with pre-radiotherapeutic PSA level of 2.1 ng/ml and a
solitary bone metastasis, 91% would irradiate the lesion
(stereotactically or fractionated), mostly also recom-
mending systemic treatment/ ADT (64%), only 9%
would not irradiate an asymptomatic bone lesion and no
one would irradiate prostatic fossa or pelvic nodes. This
would however dramatically change if the same patient
would present two additional pelvic lymph nodes: 91%
would irradiate the lymphatic drainage with a boost to
PSMA positive lesions and 75% would also irradiate the
prostatic fossa. When the same respondents were asked
about their tendency not to irradiate prostate fossa
(1 = would definitely not irradiate up to 9 = would
definitely irradiate) in a patient with high-risk features
who presented postoperative PSA persistence, this was
heavily influenced by PSMA-PET findings. In case of
lymphatic nodes restricted to the pelvis the majority
would irradiate the prostate fossa (Average value: 8.3),
however, if only extrapelvic lymph node metastases were
evident many radiation oncologists tended not to irradi-
ate (Average 4.1).
In case of the patient described above with castration
resistance and two bone lesions detected by PET, 83%
would opt for intensification of systemic treatment
and 67% would offer additional high-dose irradiation
of these lesions.
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Most dissent related to omission of radiotherapy of
the prostate fossa in case of extrapelvic PSMA positive
lesions in a high risk patient with completely resected
prostate cancer and persisting postoperative PSA.
Figure 2 depicts the willingness to omit radiotherapy to
the prostate fossa depending on PSMA-PET findings.
Conclusion
PSMA-PET should be considered the actual gold standard
for imaging of biochemical recurrent prostate cancer, out-
performing conventional imaging and Choline-PET in re-
gard to sensitivity and specificity for detection of lymph
node and distant metastases. PSMA-PET imaging should
be recommended for PSA values > 0.5 ng/ml after radical
prostatectomy. For biochemical recurrence with PSA
values < 0.5 ng/ml or treatment-naïve intermediate or
high-risk patients there is no good evidence if and when
to use PSMA-PET imaging for staging. Therefore, add-
itional clinical risk factors and potential therapeutic conse-
quences should be carefully considered for each patient.
Current clinical guidelines like the German S3 guideline
underline the importance of PSMA-PET imaging for re-
current prostate cancer, even as upfront diagnostic ap-
proach, while recommending its use in treatment-naïve
prostate cancer patient staging within prospective trials
only [47]. Initial studies with limited numbers of patients
and short follow-up time showed promising biochemical
responses in the majority of patients that were treated for
PSMA-positive recurrent tumor lesions. However, it is im-
possible to know yet if this affects overall survival. By our
short survey we identified the most critical radiation on-
cology issues: When to irradiate prostate fossa in case of
loco-regional or distant PET findings and how extensive
radiation fields should be in case of localized extrapelvic
lymph node metastasis? Additionally, there is no pub-
lished data on potential synergies of ADT and PSMA
based external beam radiotherapy as well as PSMA based
radioreceptor therapy. This should be further elucidated
by pre-clinical models and prospective clinical trials.
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